Journal of Internal Medicine Concepts & Practice ›› 2022, Vol. 17 ›› Issue (06): 425-427.doi: 10.16138/j.1673-6087.2022.06.001
• Expert forum • Next Articles
HOU Jian
Received:2021-11-22
Online:2022-12-30
Published:2023-02-27
CLC Number:
HOU Jian. The prospect of cure on multiple myeloma[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 425-427.
| [1] |
Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22(22): 5419-5427.
doi: 10.1158/1078-0432.CCR-16-0625 pmid: 28151709 |
| [2] |
Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma[J]. Mayo Clin Proc, 2004, 79(7): 867-874.
doi: 10.4065/79.7.867 pmid: 15244382 |
| [3] |
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J]. J Clin Oncol, 2014, 32(6): 587-600.
doi: 10.1200/JCO.2013.48.7934 pmid: 24419113 |
| [4] |
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12): e538-e548.
doi: 10.1016/S1470-2045(14)70442-5 URL |
| [5] |
Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma[J]. Nat Rev Dis Primers, 2017, 3: 17046.
doi: 10.1038/nrdp.2017.46 pmid: 28726797 |
| [6] |
Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage Ⅰ multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study[J]. Br J Cancer, 2000, 82(7): 1254-1260.
doi: 10.1054/bjoc.1999.1087 URL |
| [7] |
D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study[J]. Leuk Lymphoma, 2011, 52(5): 771-775.
doi: 10.3109/10428194.2011.553000 URL |
| [8] |
Witzig TE, Laumann KM, Lacy MQ, et al. A phase Ⅲ randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma[J]. Leukemia, 2013, 27(1): 220-225.
doi: 10.1038/leu.2012.236 pmid: 22902362 |
| [9] |
Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma[J]. J Clin Oncol, 2020, 38(11): 1126-1137.
doi: 10.1200/JCO.19.01740 pmid: 31652094 |
| [10] |
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(5): 548-567.
doi: 10.1002/ajh.25791 pmid: 32212178 |
| [11] |
Suzuki K, Nishiwaki K, Yano S. Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity[J]. Cancers (Basel), 2021, 13(19): 4867.
doi: 10.3390/cancers13194867 URL |
| [12] |
Caers J. The road to a cure: emerging treatments for multiple myeloma[J]. Cancers (Basel), 2020, 12(12): 3593.
doi: 10.3390/cancers12123593 URL |
| [13] |
Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis[J]. Anticancer Agents Med Chem, 2010, 10(2): 116-120.
doi: 10.2174/187152010790909344 URL |
| [14] |
Issa ME, Cretton S, Cuendet M. Targeting multiple myeloma cancer stem cells with natural products[J]. Planta Med, 2017, 83(9): 752-760.
doi: 10.1055/s-0043-109558 URL |
| [15] |
Shi F, Li M, Wang J, et al. Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles[J]. Stem Cell Res Ther, 2018, 9(1): 144.
doi: 10.1186/s13287-018-0885-2 pmid: 29784015 |
| [16] |
Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma[J]. Blood Adv, 2020, 4(23): 5988-5999.
doi: 10.1182/bloodadvances.2020002827 pmid: 33284948 |
| [17] |
Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma[J]. Blood, 2018, 132(23): 2456-2464.
doi: 10.1182/blood-2018-06-858613 pmid: 30249784 |
| [18] |
Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma[J]. J Clin Oncol, 2013, 31(20): 2540-2547.
doi: 10.1200/JCO.2012.46.2119 pmid: 23733781 |
| [19] |
Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(1): e30-e37.
doi: 10.1016/j.clml.2019.09.622 pmid: 31780415 |
| [20] |
Ghiaur G, Gerber J, Jones RJ. Concise review: cancer stem cells and minimal residual disease[J]. Stem Cells, 2012, 30(1): 89-93.
doi: 10.1002/stem.769 pmid: 22045578 |
| [21] |
Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma[J]. Nat Rev Cancer, 2017, 17(9): 543-556.
doi: 10.1038/nrc.2017.63 pmid: 28835722 |
| [22] |
Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma[J]. Int J Clin Oncol, 2015, 20(3): 413-422.
doi: 10.1007/s10147-015-0837-0 pmid: 25953678 |
| [23] |
Miething CC. Clonal evolution in myeloma[J]. Haematologica, 2019, 104(7): 1292-1293.
doi: 10.3324/haematol.2019.220152 URL |
| [24] |
Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients[J]. Haematologica, 2019, 104(7): 1440-1450.
doi: 10.3324/haematol.2018.202200 pmid: 30733268 |
| [25] |
Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma[J]. Immunol Rev, 2015, 263(1): 160-172.
doi: 10.1111/imr.12233 pmid: 25510276 |
| [26] |
Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma[J]. Curr Opin Oncol, 2020, 32(2): 170-175.
doi: 10.1097/CCO.0000000000000615 pmid: 31895122 |
| [27] |
Mahaweni NM, Ehlers FAI, Bos GMJ, et al. Tuning natural killer cell anti-multiple myeloma reactivity by targeting inhibitory signaling via KIR and NKG2A[J]. Front Immunol, 2018, 9: 2848.
doi: 10.3389/fimmu.2018.02848 pmid: 30564241 |
| [28] |
Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma[J]. Blood, 2020, 136(24): 2731-2740.
doi: 10.1182/blood.2020006540 pmid: 32645135 |
| [29] |
Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma[J]. Cancer Treat Rev, 2021, 100: 102284.
doi: 10.1016/j.ctrv.2021.102284 URL |
| [30] |
Choudhry P, Galligan D, Wiita AP. Seeking convergence and cure with new myeloma therapies[J]. Trends Cancer, 2018, 4(8): 567-582.
doi: S2405-8033(18)30127-4 pmid: 30064664 |
| [31] |
D’Agostino M, Bertamini L, Oliva S, et al. Pursuing a curative approach in multiple myeloma[J]. Cancers (Basel), 2019, 11(12): 2015.
doi: 10.3390/cancers11122015 URL |
| [32] | Munshi NC. Introduction by the guest editor[J]. Cancer J, 2019, 25(1): 1. |
| [33] |
Katodritou E, Papadaki S, Konstantinidou P, et al. Is it possible to cure myeloma without allogeneic transplantation?[J]. Transfus Apher Sci, 2016, 54(1): 63-70.
doi: 10.1016/j.transci.2016.01.015 pmid: 26850930 |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
